In a mouse model of severe TB, mTOR inhibition therapy induced host-beneficial or -detrimental effects depending on the treatment regimen; mTOR inhibition therapy reduced lung immunopathology in established infections when given in conjunction with an antimicrobial drug, but exacerbated lung damage and morbidity when administered alone in the early infection (Bhatt et al., 2021). This evidence concerns the gene MTOR and tuberculosis.